EGFR and non-small cell lung carcinoma: In 2021, two drugs against EGFR exon 20 insertion, amivantamab‐vmjw and mobocertinib, have won the U.S. FDA approval as second‐line treatment for EGFR exon 20 insertion‐positive advanced NSCLC patients.